Edap Tms NASDAQ: EDAP used its 2026 FocalTherics Investor Day to outline its shift toward becoming a “high-growth, pure-play robotic focal therapy company,” with management emphasizing the company's Focal One robotic high-intensity focused ultrasound, or HIFU, platform for prostate cancer and future indications.
EDAP TMS S.A. (EDAP) Q1 2026 Earnings Call Transcript
EDAP TMS S.A. ( EDAP ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Ryan Rhodes - CEO & Director Ken Mobeck - Chief Financial Officer Conference Call Participants John Fraunces - Lifesci Advisors, LLC Charles Wallace - H.C.
| Health Care Technology Industry | Healthcare Sector | Ryan Rhodes CEO | XSTU Exchange | US2683111072 ISIN |
| FR Country | 310 Employees | - Last Dividend | - Last Split | 31 Jul 1997 IPO Date |
EDAP TMS S.A. is an established company focusing on the development, production, marketing, distribution, and maintenance of minimally invasive medical devices aimed at the treatment of urological diseases. The company has a global presence, with operations spanning Asia, France, the United States, and other international markets. Structurally, EDAP TMS S.A. operates through three main segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). These segments represent the company's commitment to offering advanced, minimally invasive solutions for urological care. Founded in 1979, the company has its headquarters in Lyon, France, and caters to a diverse client base that includes hospitals, urology clinics, and research institutions. The firm leverages both direct marketing and sales through third-party distributors and agents to ensure its cutting-edge medical devices are accessible globally.
EDAP TMS S.A.'s HIFU segment focuses on the development, manufacturing, and marketing of medical devices that utilize high-intensity focused ultrasound technology. This technology facilitates minimally invasive treatment options for urological and other clinical indications. Within this segment, notable products include Ablatherm, a robotic HIFU device designed for the ultrasound-guided treatment of organ-confined prostate cancer, and Focal One, a robotic HIFU device primarily dedicated to the focal therapy of prostate cancer. The segment not only offers these advanced therapeutic devices but also provides disposables, leasing, treatment-related services, and maintenance services.
This division of EDAP TMS focuses on the manufacturing, marketing, and servicing of lithotripters used for the treatment of urinary tract stones through ESWL technology. The Sonolith i-move stands out as a key product in this category, offering an advanced extracorporeal shockwave lithotripter solution. Additionally, the company supplies disposable parts for lithotripters and electrodes, ensuring comprehensive support and maintenance for the longevity and efficiency of the devices.
The DIST segment operates to market, distribute, and service a range of medical products, including lasers and micro-ultrasound systems from third parties. This division extends the company's reach by offering leasing options for devices, as well as selling disposables and spare parts. It further supports its product offerings through maintenance services, thereby ensuring that clients receive end-to-end solutions for their medical device needs. Through this segment, EDAP TMS S.A. leverages its extensive sales organization and service platform to deliver quality products and excellent service to its customers.